Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial

BACKGROUND: The introduction of programmed cell death protein 1 (PD-1) blockers (i.e. nivolumab and pembrolizumab) has significantly improved the prognosis of patients with advanced melanoma. However, the long treatment duration (i.e. two years or longer) has a high impact on patients and healthcare...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulder, E. E. A. P., de Joode, K., Litière, S., ten Tije, A. J., Suijkerbuijk, K. P. M., Boers-Sonderen, M. J., Hospers, G. A. P., de Groot, J. W. B., van den Eertwegh, A. J. M., Aarts, M. J. B., Piersma, D., van Rijn, R. S., Kapiteijn, E., Vreugdenhil, G., van den Berkmortel, F. W. P. J., Hoop, E. Oomen-de, Franken, M. G., Ryll, B., Rutkowski, P., Sleijfer, S., Haanen, J. B. A. G., van der Veldt, A. A. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993897/
https://www.ncbi.nlm.nih.gov/pubmed/33765967
http://dx.doi.org/10.1186/s12885-021-08018-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993897/
https://www.ncbi.nlm.nih.gov/pubmed/33765967
http://dx.doi.org/10.1186/s12885-021-08018-w

Ejemplares similares